Business
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
The Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel, Localized Approach to Targeted Chemotherapeutic Delivery via Additional Pharmacokinetic and Pharmacodynamic DataMOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce tha
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIkpg_5WC5Ht6PAvrhd3Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"The Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel, Localized Approach to Targeted Chemotherapeutic Delivery via Additional Pharmacokinetic and Pharmacodynamic Data","length":203,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce that its abstract submission to the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 (“ASCO GI”) has been accepted.","length":445,"tagName":"p"},{"type":"text","content":"RenovoRx will present its findings from a pharmacokinetic and pharmacodynamic sub-study of the Company’s ongoing Phase III TIGeR-PaC clinical trial, led by Dr. Paula Novelli of the University of Pittsburgh Medical Center. The sub-study, titled “Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial,” compares systemic drug levels of intra-arterial gemcitabine delivered by the RenovoCath device (IAG) to the standard of care (intravenous chemotherapy) during treatment of locally advanced pancreatic cancer (LAPC).","length":606,"tagName":"p"},{"type":"text","content":"“This clinical data abstract further contributes to scientific basis for reported decreased clinical side effect profile with our approach to targeted drug-delivery via the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform and IAG versus the standard of care, systemic intravenous therapy, which is demonstrated by decreased systemic drug levels compared to treatment delivered by systemic therapy,” said Dr. Ramtin Agah, Re...